.webp)
Dental implant surgery is a surgical procedure. Its outcome is influenced not only by the quality of the implant system and the skill of the surgeon, but by the patient's systemic health — factors that affect how bone heals, how tissue integrates, and how the immune system responds to a foreign body. A thorough pre-implant health evaluation is not an administrative formality; it is the clinical process that identifies risk factors, determines whether modification is needed before proceeding, and protects the patient from complications that are substantially more manageable when anticipated than when they occur post-surgically.
Diabetes and Blood Sugar Control
Diabetes affects implant outcomes through two mechanisms: impaired microvascular circulation reduces oxygen and nutrient delivery to healing tissues, and dysregulated immune response increases susceptibility to peri-implant infection. The relevant clinical measure is HbA1c (glycated haemoglobin), which reflects average blood sugar control over the preceding 3 months.
For patients with well-controlled diabetes (HbA1c ≤7–8%), published implant survival rates are comparable to non-diabetic patients. For patients with poorly controlled diabetes (HbA1c >9%), osseointegration failure rates increase meaningfully and peri-implantitis risk is substantially higher. Our standard protocol is to request an HbA1c reading at consultation; if blood sugar is poorly controlled, implant placement is deferred until control improves. This is not a blanket exclusion of diabetic patients — it is a clinical threshold that protects the patient’s investment. For how these conditions interact with All-on-4 treatment specifically, see our pre-existing conditions guide.
Bisphosphonate and Antiresorptive Medications
Bisphosphonates (alendronate, risedronate, zoledronate) and other antiresorptive medications are prescribed for osteoporosis, Paget’s disease, and some bone metastasis protocols. They inhibit osteoclast activity — the bone-resorbing cells — which reduces bone turnover and impairs healing of surgical wounds in the jaw. The associated risk, medication-related osteonecrosis of the jaw (MRONJ), is rare but serious.
Risk stratification depends on: the specific medication (oral bisphosphonates have lower risk than IV zoledronate), the duration of use, the dose, and the presence of other risk factors (corticosteroid use, diabetes, smoking). For patients on low-dose oral bisphosphonates for fewer than 3–4 years, implant placement is generally considered acceptable with appropriate informed consent. For patients on high-dose or IV antiresorptives, or on any bisphosphonate for extended periods, we discuss the specific risk profile at consultation and may coordinate with the prescribing physician.
Smoking
Smoking impairs bone healing through multiple mechanisms: nicotine reduces blood flow to the periosteum; smoking increases oxidative stress at healing sites; the immunosuppressive effects of tobacco increase infection risk; and nicotine’s vasoconstrictive effects reduce early bone vascularisation around the implant.
Published data consistently shows higher implant failure rates in smokers vs. non-smokers — approximately 2–3 times higher in heavy smokers. For patients who smoke, we require a period of smoking cessation before and after implant surgery (typically 2 weeks before; 8 weeks after as a minimum). Patients who continue smoking during the osseointegration phase accept a substantially elevated risk of failure. We communicate this directly and honestly.
Immunocompromised Patients
Patients undergoing active chemotherapy, recent head-and-neck radiation therapy, or on long-term high-dose immunosuppressive medications present modified healing environments. Active chemotherapy is generally a contraindication to elective implant surgery during the treatment period due to severely compromised wound healing and infection risk. Head-and-neck radiation affects bone vascularity in the irradiated field; the relevant factors are dose, field, and time elapsed since treatment.
These are not absolute exclusions but require case-by-case assessment, often in coordination with the patient’s oncologist or treating physician.
Anticoagulant and Antiplatelet Medications
Patients on warfarin, newer oral anticoagulants (NOACs), or antiplatelet agents (aspirin, clopidogrel) have modified bleeding risk at surgery. The standard approach is not to stop these medications — stopping anticoagulation carries its own cardiac or thromboembolic risk — but to assess the degree of anticoagulation (INR for warfarin patients) and plan surgery accordingly with appropriate haemostatic protocols. At Dazzle, we coordinate with the patient’s cardiologist or prescribing physician where modification of the anticoagulation regimen is indicated.
Periodontal Disease History
Active periodontal disease in remaining teeth is a contraindication to implant placement — not because it prevents osseointegration mechanically, but because the same bacterial species that cause periodontitis cause peri-implantitis, and their presence in the oral environment increases the risk of early implant infection. Periodontal disease must be treated and controlled before implants are placed. Patients with a history of aggressive periodontitis require more intensive pre-implant periodontal treatment and closer post-implant monitoring.
General Health Disclosures
Patients are asked to disclose all current medications and all medical conditions at consultation. Some conditions that patients don’t consider relevant — thyroid conditions, autoimmune diseases, sleep apnoea, cardiac conditions — are relevant to anaesthesia management and recovery planning. Allergies to metals, anaesthetic agents, or antibiotics need to be known before surgery. The health questionnaire is not bureaucracy; it is clinical data that shapes the treatment plan.
FAQs
Q1: I have controlled type 2 diabetes. Can I still have implants?
In most cases, yes. Well-controlled diabetes (HbA1c ≤7–8%) is not a contraindication to implant treatment. We request an HbA1c reading before planning surgery; if your control is good, we proceed with standard protocols. We’ll also coordinate timing around your diabetes management to optimise healing conditions.
Q2: I take alendronate for osteoporosis. Is this a problem?
Oral alendronate at standard osteoporosis doses for under 3–4 years represents a low MRONJ risk. Many patients on this medication have implants placed successfully. However, the assessment is specific to your dose, duration, and other risk factors. Bring your medication information to consultation and we will give you a specific risk assessment.
Q3: I smoked for years but stopped 6 months ago. Does my past smoking history still affect my risk?
After 6 months of cessation, the acute vascular and immunosuppressive effects of smoking have largely resolved. Former smokers who have been smoke-free for 6+ months have implant success rates closer to never-smokers than to current smokers. Your cessation is clinically meaningful — good timing.
Q4: Do I need to stop any medications before implant surgery?
In most cases, no. The specific medications that require management around surgery (anticoagulants, certain immunosuppressants) are assessed case-by-case. We provide clear pre-operative instructions specific to your medication profile after your consultation.
.jpg)
